FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130646029> ?p ?o ?g. }

• W2130646029 endingPage "182" @default.
• W2130646029 startingPage "179" @default.
• W2130646029 abstract "High-dose methotrexate (HDMTX), adriamycin (ADR), and cisplatinum (CDDP) are effective agents in the treatment of osteogenic sarcoma (OS). Individual patient doses are determined by prior successful clinical trials but may be reduced due to ongoing toxicities. It is unknown whether individualized dose reductions of these drugs influence disease outcome. We retrospectively studied 27 consecutively enrolled children treated with HDMTX, ADR, and CDDP as adjuvant chemotherapy for OS, for correlations between disease outcome and several characteristics of drug, dosing: the cumulative MTX, CDDP, and ADR doses administered and the mean MTX blood levels for each patient. With a median follow-up of 59 months, the actuarial overall and disease-free survival rates were 70% and 59%, respectively. Factors which favorably influenced prognosis on univariate analysis were a cumulative ADR dose of >300 mg/m2 (P = 0.0002) and a cumulative MTX dose > 114 gm/m2 (P = 0.0048). By multivariate analysis only the cumulative ADR dose >300 mg/m2 retained prognostic value. We conclude that adjuvant chemotherapy dosages may need to be adjusted for therapeutic efficacy in addition to adjustments made for toxicity. The effect of different cumulative HDMTX and ADR dosages on prognosis in osteosarcoma patients needs to be evaluated in a prospective trial. Med. Pediatr. Oncol. 28:179–182 © 1997 Wiley-Liss, Inc." @default.
• W2130646029 created "2016-06-24" @default.
• W2130646029 creator A5014508093 @default.
• W2130646029 creator A5024345571 @default.
• W2130646029 creator A5031556203 @default.
• W2130646029 creator A5058962523 @default.
• W2130646029 creator A5078090612 @default.
• W2130646029 creator A5089669321 @default.
• W2130646029 date "1997-03-01" @default.
• W2130646029 modified "2023-09-25" @default.
• W2130646029 title "Prognostic significance of chemotherapy dosage characteristics in children with osteogenic sarcoma" @default.
• W2130646029 cites W1810454109 @default.
• W2130646029 cites W1944507750 @default.
• W2130646029 cites W1954845453 @default.
• W2130646029 cites W1968195674 @default.
• W2130646029 cites W1970133810 @default.
• W2130646029 cites W1974907966 @default.
• W2130646029 cites W1998050689 @default.
• W2130646029 cites W1998666925 @default.
• W2130646029 cites W2004261585 @default.
• W2130646029 cites W2004637354 @default.
• W2130646029 cites W2033218056 @default.
• W2130646029 cites W2043200680 @default.
• W2130646029 cites W2059524192 @default.
• W2130646029 cites W2082784075 @default.
• W2130646029 cites W2113211750 @default.
• W2130646029 cites W2142136189 @default.
• W2130646029 cites W2164650822 @default.
• W2130646029 cites W2198846739 @default.
• W2130646029 cites W2222995977 @default.
• W2130646029 cites W2329218644 @default.
• W2130646029 cites W2329552021 @default.
• W2130646029 cites W2338213887 @default.
• W2130646029 cites W4293241248 @default.
• W2130646029 cites W4297953074 @default.
• W2130646029 doi "https://doi.org/10.1002/(sici)1096-911x(199703)28:3<179::aid-mpo4>3.0.co;2-g" @default.
• W2130646029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9024512" @default.
• W2130646029 hasPublicationYear "1997" @default.
• W2130646029 type Work @default.
• W2130646029 sameAs 2130646029 @default.
• W2130646029 citedByCount "13" @default.
• W2130646029 countsByYear W21306460292012 @default.
• W2130646029 countsByYear W21306460292013 @default.
• W2130646029 countsByYear W21306460292014 @default.
• W2130646029 crossrefType "journal-article" @default.
• W2130646029 hasAuthorship W2130646029A5014508093 @default.
• W2130646029 hasAuthorship W2130646029A5024345571 @default.
• W2130646029 hasAuthorship W2130646029A5031556203 @default.
• W2130646029 hasAuthorship W2130646029A5058962523 @default.
• W2130646029 hasAuthorship W2130646029A5078090612 @default.
• W2130646029 hasAuthorship W2130646029A5089669321 @default.
• W2130646029 hasConcept C126322002 @default.
• W2130646029 hasConcept C141071460 @default.
• W2130646029 hasConcept C142724271 @default.
• W2130646029 hasConcept C143998085 @default.
• W2130646029 hasConcept C144301174 @default.
• W2130646029 hasConcept C151032500 @default.
• W2130646029 hasConcept C162156334 @default.
• W2130646029 hasConcept C188816634 @default.
• W2130646029 hasConcept C2776694085 @default.
• W2130646029 hasConcept C2777288759 @default.
• W2130646029 hasConcept C2777760704 @default.
• W2130646029 hasConcept C2777863537 @default.
• W2130646029 hasConcept C2781059491 @default.
• W2130646029 hasConcept C29730261 @default.
• W2130646029 hasConcept C38180746 @default.
• W2130646029 hasConcept C71924100 @default.
• W2130646029 hasConcept C90924648 @default.
• W2130646029 hasConceptScore W2130646029C126322002 @default.
• W2130646029 hasConceptScore W2130646029C141071460 @default.
• W2130646029 hasConceptScore W2130646029C142724271 @default.
• W2130646029 hasConceptScore W2130646029C143998085 @default.
• W2130646029 hasConceptScore W2130646029C144301174 @default.
• W2130646029 hasConceptScore W2130646029C151032500 @default.
• W2130646029 hasConceptScore W2130646029C162156334 @default.
• W2130646029 hasConceptScore W2130646029C188816634 @default.
• W2130646029 hasConceptScore W2130646029C2776694085 @default.
• W2130646029 hasConceptScore W2130646029C2777288759 @default.
• W2130646029 hasConceptScore W2130646029C2777760704 @default.
• W2130646029 hasConceptScore W2130646029C2777863537 @default.
• W2130646029 hasConceptScore W2130646029C2781059491 @default.
• W2130646029 hasConceptScore W2130646029C29730261 @default.
• W2130646029 hasConceptScore W2130646029C38180746 @default.
• W2130646029 hasConceptScore W2130646029C71924100 @default.
• W2130646029 hasConceptScore W2130646029C90924648 @default.
• W2130646029 hasIssue "3" @default.
• W2130646029 hasLocation W21306460291 @default.
• W2130646029 hasLocation W21306460292 @default.
• W2130646029 hasOpenAccess W2130646029 @default.
• W2130646029 hasPrimaryLocation W21306460291 @default.
• W2130646029 hasRelatedWork W155906731 @default.
• W2130646029 hasRelatedWork W1717046263 @default.
• W2130646029 hasRelatedWork W1993585353 @default.
• W2130646029 hasRelatedWork W2130646029 @default.
• W2130646029 hasRelatedWork W2361700749 @default.
• W2130646029 hasRelatedWork W2378425332 @default.
• W2130646029 hasRelatedWork W2384367921 @default.
• W2130646029 hasRelatedWork W2419459754 @default.

• next